Benuvia

Benuvia is a private, specialized CDMO headquartered in Austin, Texas, founded in 2018 to serve the controlled substance pharmaceutical sector. The company operates an integrated services platform covering API process development, analytical and formulation development, manufacturing, and regulatory support, all within a secure, 83,000 sq ft US facility licensed for Schedules I-V. Positioned as an enabler for biotech and pharma companies, Benuvia is a capital-intensive service provider, not a drug developer, and its success is tied to the growth of the psychedelics and cannabinoids therapeutics market. With over 500 FDA submissions cited and significant infrastructure investment, it targets clients from IND-enabling studies through commercial scale-up.

Integrated CDMO platform for controlled substances, offering API process development, analytical/formulation development, cGMP manufacturing (Schedules I-V), and regulatory services under a unified model with specialized programs (Discovery Booster, Clinical Expressway, Market Accelerator).

Benuvia competes in the niche of controlled substance CDMOs against a limited set of specialized players and may face future competition from larger, diversified CDMOs expanding into this space. Its key differentiators are its integrated US platform, specific expertise in Schedules I-V, and a track record of over 500 FDA submissions for complex molecules.